INTENT Biologics Receives FDA Breakthrough Therapy Designation for PEP Biologic™ for its Phase 3 Ready Flagship IndicationINTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PEP Biologic™ for the treatment of diabetic foot ulcers (DFU) under IND 019567.
